MX9301500A - Anticuerpos construidos con ingenieria genetica - Google Patents

Anticuerpos construidos con ingenieria genetica

Info

Publication number
MX9301500A
MX9301500A MX9301500A MX9301500A MX9301500A MX 9301500 A MX9301500 A MX 9301500A MX 9301500 A MX9301500 A MX 9301500A MX 9301500 A MX9301500 A MX 9301500A MX 9301500 A MX9301500 A MX 9301500A
Authority
MX
Mexico
Prior art keywords
genetic engineering
antibodies
derivatives
melanoma
built
Prior art date
Application number
MX9301500A
Other languages
English (en)
Inventor
Norman Hardman
Gerd Pluschke
Brendan Murray
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of MX9301500A publication Critical patent/MX9301500A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención se refiere a anticuerpos antiidiotípicos que comprenden regiones variables en murinos que presentan la imagen interna del antígeno humano asociado con melanoma de alto peso molecular, y derivados del mismo que tienen especificidad para dicho anticuerpo. estos anticuerpos monoclónicos antiidiotípicos y sus derivados tienen funciones inmuno-regulatorias y, por l tanto, se pueden utilizar con propósitos de diagnóstico y terapéuticos, tales como el tratamiento de melanoma.
MX9301500A 1992-03-17 1993-03-17 Anticuerpos construidos con ingenieria genetica MX9301500A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92810188 1992-03-17

Publications (1)

Publication Number Publication Date
MX9301500A true MX9301500A (es) 1993-12-01

Family

ID=8211884

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9301500A MX9301500A (es) 1992-03-17 1993-03-17 Anticuerpos construidos con ingenieria genetica

Country Status (12)

Country Link
US (1) US5866124A (es)
EP (1) EP0640131B1 (es)
JP (1) JPH07504802A (es)
AT (1) ATE179210T1 (es)
AU (1) AU673347B2 (es)
CA (1) CA2130173A1 (es)
DE (1) DE69324579T2 (es)
DK (1) DK0640131T3 (es)
ES (1) ES2131107T3 (es)
GR (1) GR3030702T3 (es)
MX (1) MX9301500A (es)
WO (1) WO1993019180A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06506947A (ja) * 1991-04-18 1994-08-04 マウント　シナイ　スクール　オブ　メディスン　オブ　ザ　シティー　ユニバーシティー　オブ　ニューヨーク 抗ウィルスハイブリッド抗体
EP0674907A3 (en) * 1994-03-21 1996-03-13 Ciba Geigy Ag Antibody-carrier protein conjugates, for use in active immunotherapy.
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
EP1871882A1 (en) * 2005-03-25 2008-01-02 GlycArt Biotechnology AG Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
RU2006112025A (ru) * 2005-12-16 2007-10-27 Хелт Рисерч Инк. (Us) Пептиды для стимуляции иммунного ответа против меланомы
US8476410B2 (en) * 2008-10-16 2013-07-02 University of Pittsburgh—of the Commonwealth System of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
CA2848842C (en) 2011-10-04 2020-09-29 King's College London Ige anti -hmw-maa antibody
JP6956631B2 (ja) 2014-09-15 2021-11-02 アムジェン インコーポレイテッド 二重特異性抗ｃｇｒｐ受容体／ｐａｃ１受容体抗原結合タンパク質及びその使用
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AU2019246983A1 (en) 2018-04-02 2020-10-29 Amgen Inc. Erenumab compositions and uses thereof
CN115349490B (zh) * 2022-07-14 2024-01-12 成都中医药大学 一种卵巢储备功能低下动物模型的建立方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE45285T1 (de) * 1983-11-07 1989-08-15 Wistar Inst Durch antiidiotype antikoerper induzierte immune antwort zu tumoren und viren.
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
DE68920016T2 (de) * 1988-05-17 1995-04-20 Soldano Ferrone Anti-idiotyp-antikörper gegen antimenschliche hochmolekulare, an melanomen assoziierte antigene.
DK0493446T3 (da) * 1989-09-15 1997-08-11 Tanox Biosystems Inc Behandling af autoimmunsygdom.
ATE132906T1 (de) * 1989-11-14 1996-01-15 New York Medical College Neuartige antiidiotypische monoklonale antikörper

Also Published As

Publication number Publication date
WO1993019180A1 (en) 1993-09-30
EP0640131B1 (en) 1999-04-21
US5866124A (en) 1999-02-02
DK0640131T3 (da) 1999-11-01
AU3631393A (en) 1993-10-21
ATE179210T1 (de) 1999-05-15
CA2130173A1 (en) 1993-09-30
DE69324579D1 (de) 1999-05-27
AU673347B2 (en) 1996-11-07
EP0640131A1 (en) 1995-03-01
ES2131107T3 (es) 1999-07-16
GR3030702T3 (en) 1999-11-30
JPH07504802A (ja) 1995-06-01
DE69324579T2 (de) 1999-09-23

Similar Documents

Publication Publication Date Title
MX9301500A (es) Anticuerpos construidos con ingenieria genetica
PT1231268E (pt) Bancos de anticorpos policlonais
ES2126145T3 (es) Redireccionamiento de anticuerpos.
ATE141329T1 (de) Rekombinante antikörper spezifisch für einen wachstumsfaktor-rezeptor
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
DE69633717D1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
DE3852054D1 (de) Monoklonale Antikörper gegen Glycolipid-Antigene und ihre Verwendung.
ATE71410T1 (de) Tumorspezifische monoklonale antikoerper.
ATE132197T1 (de) Monoklonale antikörper
ATE197592T1 (de) Monoklonaler antikörper gegen cd44v6
MX9306220A (es) Ptp 1d: una proteina tirosina fosfatasa novedosa.
ATE466031T1 (de) Anti-hgf-r-antikörper und deren verwendung
Kennedy et al. Anti-idiotypes and immunity
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
DE59504707D1 (de) Arzneimittel für die verlängerte immunsuppression und tumorzellelimination
DE50114906D1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur stimulation von blutzellen, welche kein cd28 tragen
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
ATE58172T1 (de) Monoklonale antikoerper gegen alpha-2 interferon und hybridomas, die solche antikoerper produzieren.
ATE94880T1 (de) Synthetische peptide, gegen diese gerichtete antikoerper und deren verwendung.
ES2059418T3 (es) Antigeno asociado a carcinoma humano y anticuerpo asociado al antigeno.
DE3750225D1 (de) Herstellung und verwendung von anti-helminthischen wirkstoffen und schutzantigenen.
DE59712847D1 (de) Monoklonaler Antikörper gegen MxA und MxB
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
Ponzetto et al. Clinical phenotype of Graves’ disease
ATE97959T1 (de) Monoklonale antikoerper gegen menschliche alphaatrialnatri¨retic-polypeptide und entsprechende hybridome, deren herstellung und verwendung.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees